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Background-—Diabetes mellitus (DM) has multifactorial detrimental effects on myocardial tissue. Recently, carbonic anhydrases
(CAs) have been shown to play a major role in diabetic microangiopathy but their role in the diabetic cardiomyopathy is still unknown.
Methods and Results-—We obtained left ventricular samples from patients with DM type 2 (DM-T2) and nondiabetic (NDM)
patients with postinfarct heart failure who were undergoing surgical coronary revascularization. Myocardial levels of CA-I and CA-II
were 6- and 11-fold higher, respectively, in DM-T2 versus NDM patients. Elevated CA-I expression was mainly localized in the
cardiac interstitium and endothelial cells. CA-I induced by high glucose levels hampers endothelial cell permeability and determines
endothelial cell apoptosis in vitro. Accordingly, capillary density was significantly lower in the DM-T2 myocardial samples
(meanSE=2152146 versus 4545211/mm2). On the other hand, CA-II was mainly upregulated in cardiomyocytes. The latter
was associated with sodium-hydrogen exchanger-1 hyperphosphorylation, exaggerated myocyte hypertrophy (cross-sectional area
56534 versus 41227 lm2), and apoptotic death (83054 versus 47034 per 106 myocytes) in DM-T2 versus NDM patients.
CA-II is activated by high glucose levels and directly induces cardiomyocyte hypertrophy and death in vitro, which are prevented by
sodium-hydrogen exchanger-1 inhibition. CA-II was shown to be a direct target for repression by microRNA-23b, which was
downregulated in myocardial samples from DM-T2 patients. MicroRNA-23b is regulated by p38 mitogen-activated protein kinase,
and it modulates high-glucose CA-II–dependent effects on cardiomyocyte survival in vitro.
Conclusions-—Myocardial CA activation is significantly elevated in human diabetic ischemic cardiomyopathy. These data may open
new avenues for targeted treatment of diabetic heart failure. ( J Am Heart Assoc. 2014;3:e000434 doi: 10.1161/JAHA.
113.000434)
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T he global prevalence of diabetes mellitus (DM) isforecast to reach 300 million by 2025, and more than
three-fourths of deaths among this population are expected to
result from cardiovascular disease.1 Individuals with DM are
indeed at a significantly greater risk of developing both
microvascular and macrovascular disease, and they have an
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excess morbidity and mortality for coronary artery disease
(CAD) and post–myocardial infarction (MI) heart failure.2,3
Increased reactive oxygen species (ROS) production in the
diabetic heart is a contributing factor in the development and
progression of diabetic cardiomyopathy.4–6 Cumulative super-
oxide-mediated damage or cellular dysfunction results when
ROS generation supersedes ROS-degrading pathways. Ische-
mic injury in DM is typically accompanied by a deeper grade
of myocardial tissue hypoxia, generating increased ROS
production, which in turn activates maladaptive signaling
pathways, leading to myocardial cell death and maladaptive
cardiac remodelling.7 Carbonic anhydrases (CAs) are a family
of ubiquitous metalloenzymes that are responsible for the
rapid conversion of carbon dioxide to bicarbonate and protons
and thus are involved in a variety of physiological and
pathological processes that involve pH regulation, CO2 and
HCO3
 transport, ion transport, and biosynthetic reactions.8
The CA inhibitor ethoxyzolamide prevents rat cardiomyocyte
hypertrophy in vitro and reverses it once it is established.9
Elevated CA-II expression has been detected in rats with
spontaneous hypertension and heart failure.10 Mice that
develop angiotensin II–induced cardiac hypertrophy and
age-dependent dilated cardiomyopathy show increased
expression of CA-II and other CAs.11 Overexpression of a
catalytically inactive dominant negative CA-II suppresses the
response to hypertrophic stimuli in rat cardiomyocytes in
vitro.12 Furthermore, CA-II–deficient (Car2) mice exhibit
physiological cardiac hypertrophy without any decrease in
cardiac function, and isolated cardiomyocytes from Car2 mice
do not respond to prohypertrophic stimulation.12 Concur-
rently, there was a recent report that CA-II and CA-IV mRNA
levels are significantly increased in hypertrophied and failing
human hearts of ischemic and nonischemic origin, proposing
CA-II as biomarker for the early detection of myocyte
hypertrophy and heart failure.13 CAs work with the Anion
Exchange 3 Cl/HCO3
 exchanger and Na+/H+ exchanger 1
(NHE-1) to promote cardiomyocyte hypertrophy.14 Indeed,
cytosolic CA-II activates NHE-1,15 which is a cardiac-specific
integral membrane glycoprotein of the NHE family.14 Different
forms of myocardial stress, including ischemia, lead to ROS
generation and NHE-1 hyperactivity, which results in further
ROS generation and Ca2+ overload, myocardial dysfunction,
hypertrophy, apoptosis, and failure.14,16 Recently, CA-I
increased concentration, and activity has been shown to be
detrimental in diabetic retinopathy.17 However, the expres-
sion and activity status of CAs in ischemic myocardium of
patients with DM are currently unknown.
In the present study, we assessed CA-I and CA-II expres-
sion in human cardiac samples from post-MI patients with or
without DM type 2 (DM-T2). Here, we determined whether
CA-I myocardial expression correlates with capillary density
and endothelial cell death in DM. Also, we evaluated NHE-1
activation in human diabetic ischemic cardiomyopathy and its
dependence from CA-II activity in cardiomyocytes. Finally, we
endeavored to uncover the specific molecular mechanisms
underlying CA-II modulation in DM.
Methods
Patient Selection and Cardiac Sample Collection
Left ventricular cardiac biopsy samples were derived from
patients affected by post-MI cardiomyopathy undergoing
surgical coronary revascularization as described previously.18
For each patient, 6 biopsy samples were harvested: 3 from
the infarct border area (peri-infarct zone) and 3 from the
nonischemic, remote myocardium (remote zone). Samples
were either immediately snap-frozen in liquid nitrogen and
stored at 80°C until processed for RNA or protein extraction
or formalin-fixed for immunohistochemistry analysis. Patients
with DM-T2 (n=20) and without diabetes (NDM, n=20) were
included in the study and did not differ significantly in any
clinical parameter other than the presence of DM-T2 (Table).
All diabetic patients were treated with oral hypoglycemic
agents and had an acceptable glycemic control (HbA1c <8%),
and for 72 hours after surgery they received insulin therapy.
Bioptic specimens were taken after informed consent
disclosing future use for research. The investigation con-
formed to the principles outlined in the Helsinki Declaration
and to Italian laws and guidelines and was authorized by the
Ethical Committee of the Second University of Naples, Italy.
Histology and Immunohistochemical Analysis
Bioptic samples were washed with PBS and fixed in 10%
formalin, and paraffin-embedded. 5-lm sections were pre-
pared on a microtome (Leika) and mounted onto microscope
slides.19,20
To identify and localize CA-I, CA-II, and NHE-1, human
cardiac sections were stained with antibodies against CA-I,
CA-II, and NHE-1 (anti-human CA-I antibody, Abcam; anti-
human CA-II antibody, R&D Systems; rabbit polyclonal anti–
NHE-1, Santa Cruz Biotechnology). Cardiac myocytes were
identified with antibodies against a–sarcomeric actin (Sigma),
cardiac troponin I (Santa Cruz Biotechnology), or slow
(cardiac) myosin heavy chain (Sigma).19,20 Endothelial cells
and capillaries were detected by staining for von Wildebrand
factor (vWF) (rabbit polyconal, Dako). Images were acquired
using a confocal microscopy (Zeiss 710 LSM); 3 slides per
sample were assessed.
To assess cardiomyocyte size, sections were stained with
hematoxylin and eosin (H&E), according to standard proce-
dures.20 Myocyte diameter was measured across the nucleus
in 3 transverse H&E sections per sample, on a light
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microscope (Nikon E1000M) using Lucia G software. A total of
300 myocytes per section were analyzed for each sample.
The density of capillaries in the infarct region was
evaluated by staining with an antibody against vWF (Dako).20
The secondary antibody used was a donkey anti-rabbit,
conjugated with horseradish peroxidase (Santa Cruz). Endog-
enous peroxidase in the section was blocked with 3%
hydrogen peroxide in PBS for 15 minutes at room tempera-
ture. The chromogen 3,3′-diaminobenzidine (DAB, Sigma) was
used to visualize the blood vessels. The slides were count-
erstained with hematoxylin for identification of nuclei before
being examined by using light microscopy. The number of
capillaries (defined as 1 or 2 endothelial cells spanning the
vWF-positive vessel circumference) was determined by count-
ing 10 fields per section at 940 magnification. A total of 3
slides per sample were assessed. The amount of capillaries
was expressed per mm2.
To detect myocyte cell apoptosis, sections were stained
with rabbit anti-human activated caspase-3 primary antibody
(R&D Systems).20 The chromogen DAB (Sigma) were used to
visualize the apoptotic cardiomyocytes. Sections were then
counterstained with hematoxylin and permanently mounted
before being examined with light microscopy. Further, parallel
staining using fluorescence detection was instituted to
measure activated caspase-3–positive apoptotic myocytes
with confocal microscopy. The number of caspase-3–positive
myocytes was determined by counting 20 random fields per
section at 940 magnification. A total of 3 slides per sample
were assessed. The amount of caspase-3–positive myocytes
was expressed as percentage relative to the total number of
myocytes counted.
Endothelial cell apoptosis was detected by use of the
terminal deoxynucleotidyl transferase (TdT) assay kit (Roche)
or caspase 3 staining.19,20 Apoptotic endothelial cells were
counterstained with a vWF antibody (Dako) and quantified
using confocal microscopy.20
Immunoblots and Immunoprecipitation
For immunoblotting, cardiac samples (or cells) were homoge-
nized and proteins were extracted as previously described.18,21
After PAGE, proteins were transferred and exposed to rabbit
polyclonal CA-II antibody (Abcam), mouse monoclonal CA-I
(Abcam), ERK1/2 (Cell Signaling) antibodies, and rabbit
polyclonal p-38, phospho-p-38, JNK, phospho-JNK, and
phospho-ERK1/2 (Cell Signaling) antibodies. Blots were
incubated with the primary antibody, at a concentration
suggested by the manufacturers, overnight at 4°C in Tris-
buffered saline with Tween (TBS-T), 5% nonfat dried milk. After
extensive washing in TBS-T, blots were incubated with the
secondary antibody (horseradish peroxidase–conjugated anti-
mouse or anti-rabbit immunoglobulins, Santa Cruz Biotech-
nology) at a dilution of 1:1000 for 45 minutes at room
temperature. Specific proteins were detected by enhanced
chemiluminescence (Amersham) and evaluated by using
densitometry.
For immunoprecipitation of NHE-1 and immunoblotting for
phospho-serine, myocardial protein extracts were incubated
overnight at 4°C with mouse monoclonal anti–NHE-1 (Santa
Cruz Biotechnology). Subsequently, protein A–agarose was
added. Immunoprecipitated proteins were separated on 8%
SDS-PAGE, transferred onto nitrocellulose filters, and exposed
to rabbit polyclonal anti–phospho-serine antibodies (Cell
Signaling).19,21
Quantitative Real-Time RT-PCR
RNA was extracted from human cardiac samples or cultured
cells using Qiagen RNeasy columns and was reverse
transcribed using first-strand cDNA synthesis with random
or oligo-dT primers (Applied Biosystems).18 Quantitative





Sex, M/F 10/10 10/10
Age, y 64.32.1 62.62.3
Duration of diabetes, y 9.21.1 —
BMI, kg/m2 28.90.9 27.20.7
HbA1c, % 7.20.1 5.30.1*
FBG, mg/dL 151.39.5 81.53.9*
LDL cholesterol, mg/dL 132.37.1 1285.1
HDL cholesterol, mg/dL 43.31.6 48.21.8*
TG, mg/dL 167.510.3 1268.5*
SBP, mm Hg 133.93.7 127.33.2
DBP, mm Hg 76.32.1 74.12.4
Three-vessel CHD, n 18 18







Quantitative data are expressed as meanSE. Binary data are reported by counts.
*P<0.01 vs diabetic patients. Comparisons of the quantitative data have been made
through use of Student’s t test for independent samples. The v2 test was used to
compare binary data. BMI indicates body mass index; FBG, fasting blood glucose; LDL,
low-density lipoprotein; HDL, high-density lipoprotein; TG, triglycerides; SDP, systolic
blood pressure; DBP, diastolic blood pressure; CHD, coronary heart disease; ACEI,
angiotensin-converting enzyme-inhibitor; ARB, angiotensin II receptor blocker.
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RT-PCR (qRT-PCR) was performed using SYBR Green (Bio-Rad)
on a MyIQ thermocycler (Bio-Rad). The PCR included 2 lL of
template cDNA and 300 nmol/L forward and reverse primers.
PCR efficiency was evaluated by using a standard curve of 5
serial dilution points. Data were analyzed using Bio-Rad IQ
software, and mRNA was normalized to the housekeeping
gene GAPDH. All reactions were carried out in triplicate.
Primers were designed using the Primer 3 software, and the
specific sequences are as follows (forward, followed by
reverse primer in each case): rat GAPDH (5′-CGTCTCATAG-
ACAAGAT-3′ and 5′-TGATGGCAACAATGTCCACT-3′), rat ANF
(5′-GGGGGTAGGATTGACAGGAT-3′ and 5′-GGATCTTTTGCGAT
CTGCTC-3′), and rat CA-II (5′-ACCAGAGAACTGGCACAAGG-3′
and 5′-ATGAGCAGAGGCTGTAGGGA-3′), human CA-II (5′-CAA
TGGTCATGCTTTCAACG-3′ and 5′-CCCCATATTTGGTGTTCCAG-
3′), human Actin (5′-CCACGAAACTACCTTCAACTCC-3′ and 5′-
TCATACTCCTGCTGCTTGCTGATCC-3′), rat BNP (5′-GACGGGCT
GAGGTTGTTTTA-3′ and 5′-ACTGTGGCAAGTTTGTGCTG-3′), and
rat beta-MHC (5′-CCTCGCAATATCAAGGGAAA-3′ and 5′-TACA
GGTGCATCAGCTCCAG-3′).
Cell Culture and Reagents
Primary cultures of neonatal cardiomyocytes (nCMs) or adult
ventricular cardiomyocytes (arCMs) were prepared from
ventricles of 1- to 2-day-old or adult (9 weeks old) Wistar
rats, respectively, as previously described.20,22 Freshly iso-
lated cardiomyocytes were plated onto laminin (20 mg/mL)-
coated chamber slides at a density of 29104 cells/cm2 and
were cultured in DMEM, containing 10% FBS and 0.1%
penicillin-streptomycin, at 37°C, in an atmosphere containing
5% CO2. Human coronary endothelial cells (hCECs) were
obtained from Cell Applications.
6-Ethoxyzolamide (ETZ), [5-(2-methyl-5-fluorophenyl)furan-
2-ylcarbonyl]guanidine (KR-32568, an NHE-1 inhibitor), and
human recombinant CA-I were obtained from Sigma.
Human CA-II and rat CA-IIshRNA plasmids were obtained
from Origene, and short hairpin RNA (shRNA) construct to
silence CA-I (CA-IshRNA) was purchased from Sigma–Aldrich.
Efficiency of plasmid construct transfection was verified by
green fluorescence protein (GFP) fluorescence of nCM or
arCMs transfected with a plasmid encoding the GFP. An
empty plasmid vector was used as additional control.
Endothelial Cell Permeability and Apoptotic Death
Human recombinant CA-I protein (Sigma) was added at
100 lmol/L to hCEC culture in vitro. Permeability across
endothelial cell monolayers was measured using gelatin-
coated Transwell units (Boyden chambers) (6.5-mm diameter,
0.4-lm-pore polycarbonate filter; Corning Costar), as previ-
ously described.23 Briefly, hCECs were plated at a density of
0.69105 cells (or 19105 in the case of transduced cells) per
well (upper chamber) and were cultured for 3 days until a
tight monolayer formed. Endothelial permeability was deter-
mined by measuring the passage of FITC-labeled dextran
(1 mg/mL of fluorescein isothiocyanate-dextran, molecular
mass 40 kDa; Sigma–Aldrich) through the hCEC monolayer.
Then, NG or HG (NG: low/normal, 5.5 mmol/L glucose; HG:
high, 33 mmol/L glucose) was added to the upper chamber in
the presence of 1 mg/mL FITC-labeled dextran. After 30 min-
utes of treatment, 100 lL was collected from the lower
compartment and fluorescence was evaluated using a Fluo-
roskan Ascent Microplate Fluorometer following the manu-
facturer’s protocol (Thermo Scientific).
hCEC apoptosis were detected using the terminal deoxy-
nucleotide transferase–mediated dUTP nick-end labeling
assay20 48 hours after NG or HG stimuli. Quantitative
data are expressed as meanSE from 4 independent
experiments.
Cardiomyocyte Hypertrophy and Apoptosis
In Vitro
nCMs were exposed to NG or HG in the presence or absence
of ETZ (100 lmol/L) or the NHE-1 inhibitor (10 lmol/L) for
48 hours. Hypertrophy was assayed by measurement of the
cell surface area of cells. Cell surface area was measured
before and after intervention with drugs. Images of cultured
cardiomyocytes were collected with a QICAM fast cooled
12-bit color camera (QImaging Corporation). Images were
analyzed with Image-Pro Plus software (Media Cybernetics)
to measure cell surface area. In each group, surface areas
were measured for 200 cells. Cell surface area (percent
relative to control)=surface area (after treatment)/surface
area (before treatment)9100. Additionally, nCMs were
incubated in the same media with 1.0 lCi/mL [3H]leucine
for 12 hours, and then processed for determination of
incorporated radioactivity after precipitation with 10% TCA as
described previously.24
Apoptotic arCMs were detected using the terminal deoxy-
nucleotide transferase–mediated dUTP nick-end labeling
assay 20 48 hours after NG or HG stimuli. The number of
positively stained cells was counted from 20 fields per slide.
When a plasmid construct was transfected, cell size, [3H]
leucine, or apoptosis rate was measured 96 hours after initial
transfection (48 hours transfection+48 hours NG or HG).
Quantitative data are expressed as meanSE from 4
independent experiments.
MicroRNA 23b Detection and Biological Function
Micro RNA (miRNA)/mRNA were extracted from cell culture
or human cardiac samples as previously described.25,26
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Specifically, for miRNA/mRNA extraction from isolated cells,
the mirVana miRNA Isolation Kit (Ambion, Inc) was used
while Trizol was used for miRNA/mRNA extraction from
solid tissues. Specific cDNA was obtained using the
high-capacity cDNA Reverse transcription kit (Applied
Biosystems). TaqMan MicroRNA Assays and TaqMan Gene
Expression Assays (Applied Biosystem) were used to quan-
tify miRNAs (miR-23b and miR-1) levels by qRT-PCR (see
earlier).
Precursor miRNA expression clone for rno-mir-23b (a
pEZX-MR04 vector expressing the specific precursor miR-23b
under the CMV promoter with an eGFP reporter gene) and
miRNA inhibitor against rno-miR-23b (a pEZX-AM04 vector
expressing the specific miR-23b inhibitor under the U6
promoter and a mCherry reporter gene) were purchased from
Tebu-Bio. A precursor miRNA scrambled control for pEZX-
MR04 and an miRNA inhibitor scrambled control clone for
pEZX-AM04 were also obtained from Tebu-Bio. In addition,
pre–miR-23b, scrambled pre-miR, anti–miR-23b, or scrambled
anti-miR was introduced into nCMs or arVMS via reverse
transfection using Lipofectamine 2000 (Invitrogen) as previ-
ously described.25,26 The miR or anti-miR transfection was
confirmed via eGFP or mCherry fluorescence and quantified
by using qRT-PCR.
Luciferase reporter and activity assay was performed as
previously described.25 Briefly, wild-type and mutant CA-II
3′-UTR sequences were cloned into luciferase-reporter con-
structs and then separately cotransfected with scrambled miR
precursor, miR-23b precursor, scrambled anti-miR, or anti–
miR-21b into C2C12 myoblasts using Lipofectamine 2000.
Forty-eight hours post-transfection, luciferase activity was
measured and normalized to b-galactosidase activity.
All the in vitro experiments were performed in quadrupli-
cate, and the data shown as meanSE.
Statistics
Statistical analysis was performed with GraphPad Prism
version 6.00 for Macintosh (GraphPad Software). Quantitative
data are reported as meanSE and binary data by counts.
Significance between 2 groups was determined by Student’s
t test or paired t test as appropriate. For comparison between
multiple groups, ANOVA was used. A P value <0.05 was
considered significant. Bonferroni post-hoc method was used
to locate the differences. In these cases, the Type 1 error
(a=0.05) was corrected by the number of statistical compar-
isons performed.
For the in vitro cell and molecular biology experiments with
an n=4 sample size, giving the low number of the sample, the
Kruskal–Wallis test (for multiple-group comparison), and the
Mann–Whitney U test (for comparison between 2 groups)
were performed.
Results
CA-I and CA-II Are Increased in Diabetic Ischemic
Cardiomyopathy
We first compared protein expression of CA-I and CA-II in the
cardiac samples from NDM and DM-T2 patients with ischemic
cardiomyopathy by using Western blot analysis. CA-I and CA-II
increased in the peri-infarct zone compared with the remote
area in both NDM and DM-T2 (Figure 1A and 1B). More
relevant, CA-I and CA-II were increased in DM-T2 compared
Figure 1. Carbonic anhydrase (CA)-I and -II are increased in
diabetic ischemic cardiomyopathy. A, Representative Western blot
showing CA-I and -II levels in the remote (R) and peri-infarct (PI) zone
of diabetes mellitus type 2 (DM-T2) and non–diabetes mellitus (NDM)
cardiac samples. B, Optical density (O.D.) analysis of CA-I and -II
protein levels in DM-T2 compared with NDM patients; *P<0.0001 vs
remote, †P<0.0001 vs NDM, n=20 per group. C, Representative
confocal microscopy image showing CA-I localization in capillary
endothelial cells in the peri-infarct area of cardiac samples from NDM
and DM-T2 patients (vWF, red fluorescence; CA-I, green fluorescence;
DAPI (40,6-diamidino-2-phenylindole), nuclei blue fluorescence); scale
bar 50 lm. D, CA-II was upregulated in cardiomyocytes from DM-T2
compared with NDM (a-SA, red fluorescence; CA-II, green fluores-
cence; DAPI, nuclei blue fluorescence); scale bar 50 lm. Quantitative
data are expressed as meanSE. CA indicates carbonic anhydrases;
vWF, von Willebrand factor.
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with NDM patients in both the remote zone and the peri-
infarct area (Figure 1A and 1B). Specifically, CA-I and CA-II
increased by 6- and 11-fold, respectively, in DM-T2 versus
NDM.
CA-I and CA-II are prevalently cytosolic CA isoforms.8 We
assessed CA-I and CA-II localization by using immunohisto-
chemistry and confocal microscopy. An increased myocardial
expression of CA-I in DM-T2 versus NDM patients was evident
whereby CA-I was prevalently detectable in the interstitial
space (Figure 1C). However, CA-I was also increased in
capillary endothelial cells in the peri-infarct area of cardiac
samples from DM-T2 compared with NDM patients (Fig-
ure 1C). On the other hand, CA-II was mostly upregulated in
cardiomyocytes from DM-T2 compared with NDM patients
(Figure 1D).
Finally, for a complete illustration of the data, all the blots
related to CA-I and CA-II expression from each patient cardiac
sample are accordingly presented with the relative semiquan-
titative analysis as box-plot graphs (Figure 2A and 2B).
CA I Mediates Endothelial Cell Death
Altered vascular permeability and endothelial dysfunction are
hallmarks of diabetic microangiopathy.4 CA-I is a key player in
mediating vascular leakage diabetic retinopathy,17 while CA-IV
has also been linked to endothelial cell apoptosis in retinitis
pigmentosa.27 We then measured the number of capillaries in
the peri-infarct zone of DM-T2 and NDM patients. Consistent
with the severe dysfunction of the microcirculation in ischemic
heart disease with diabetes,4 we detected a significant
decrease in capillary density in the peri-infarct region in DM-
T2 compared with NDM patients (Figure 3A through 3C). Also,
an increased rate of endothelial cell apoptosis in DM-T2 versus
NDM patients was detected (Figure 3D and 3E). Thus, we
Figure 2. Carbonic anhydrase (CA)-I and-II expression in all diabetic and nondiabetic patients included in the study. A, Western blot showing CA-
I and -II expression in the remote and peri-infarct (Peri-MI) zone of all diabetes mellitus type 2 (DM-T2) and non–diabetes mellitus (NDM) cardiac
samples included in the study. B, Box-plot graphs showing optical density analysis of CA-I and -II protein levels in DM-T2 compared with NDM
patients; *P<0.0001 vs remote, #P<0.0001 vs NDM, n=20 per group. MI indicates myocardial infarction.
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tested whether CA-I could directly affect endothelial cell
survival in vitro. hCECs were challenged with CA-I in vitro, and
this treatment significantly increased hCEC death at levels
comparable to those for HG (Figure 3F). Concurrently,
CA-IshRNA significantly reduced HG-induced hCEC apoptosis
in vitro (Figure 3F). Also, we ascertained whether CA-I induced
an increase in endothelial cell permeability. hCECs cultivated
as tight monolayers in Boyden chambers were challenged with
Figure 3. Carbonic anhydrase (CA)-I and decreased capillary density in diabetes mellitus type 2 (DM-T2).
A, Representative DAB staining (vWF, brown) in the peri-infarct showing capillary density in non–diabetes
mellitus (NDM); right panel shows higher magnification of the inset from left panel. B, Representative DAB
staining (vWF, brown) showing capillary density in DM-T2; right panel shows higher magnification of the inset
from left panel. Scale bar 50 lm. C, Myocardial capillary density was decreased in DM-T2 compared with
NDM patients. *P<0.0001 vs NDM, n=20 per group. D, Representative confocal microscopy image of TdT-
positive apoptotic endothelial cells in DM-T2 peri-infarct zone (vWF, white fluorescence; TdT, green
fluorescence; DAPI, nuclei blue fluorescence). Scale bar 50 lm. E, Bar graph showing increased endothelial
cell apoptosis in DM-T2 vs NDM patients; *P<0.0001 vs NDM, n=20 per group. F, CA-I treatment and CA-
IshRNA transfection on hCEC death as assessed by TdT staining; *P<0.0001 vs normal glucose (NG), NG+CA-
IshRNA, and high glucose+CA-IshRNA (HG+CA-IshRNA), n=4 per group. G, CA-I increased hCEC permeability in
the Boyden chamber in vitro *P<0.001 vs normal glucose (NG), NG+CA-IshRNA, and high glucose+CA-IshRNA
(HG+CA-IshRNA), n=4 per group. Quantitative data are expressed as meanSE. hCEC indicates human
coronary endothelial cells; DAB, 3,3′-diaminobenzidine; Tdt, terminal deoxynucleotidyl transferase; vWF, von
Willebrand factor.
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CA-I for 90 minutes, and cell permeability was determined by
measuring the passage of FITC-labeled dextran across the
endothelial cell monolayer. HG and CA-I increased hCEC
permeability and CA-IshRNA prevented the HG-induced effect
(Figure 3G). Thus, these data suggest that the increased
myocardial expression of CA-I in ischemic myocardium of
diabetic patients alters endothelial permeability and increases
endothelial cell death with a net reduction in capillary density.
Additionally, it appears that microvascular dysfunction and
leakage in DM sustain CA-I accumulation in the cardiac
interstitium (Figure 1C) through an increased ischemic hem-
orrhage and consequent erythrocyte lysis.28
Increased Myocyte CA-II Hyperphosphorylates
the NHE-1, Worsening Myocyte Hypertrophy and
Death in Diabetic Ischemic Cardiomyopathy
One of the main targets of CA-II activity in cardiomyocytes is
the NHE-1.14 Thus, we measured, through immunoprecipita-
tion and immunoblotting, the serine-phosphorylation status of
NHE-1 in diabetic versus nondiabetic myocardial samples.
NHE-1 protein expression was increased in both remote and
peri-infarct areas of DM-T2 samples compared with NDM
samples (Figure 4A through 4D). More importantly, NHE-1
was hyperphosphorylated in T2-DM versus NDM (Figure 4A
Figure 4. Myocyte NHE-1 is hyper-phosphorylated in diabetic ischemic cardiomyopathy. A, Representative WB analysis showing NHE-1 protein
expression and phosphorylation (immunoprecipitation, IP, with NHE-1 antibody and immunoblot, IB, with phospho-serine, p-ser, antibody) in both
remote and peri-infarct areas of DM-T2 samples compared with NDM. B, Bar graph showing optical density analysis of NHE-1 protein expression n
DM-T2 and NDM samples; *P<0.0001 vs remote, #P<0.0001 vs NDM, n=20 per group. C, Bar graph showing optical density analysis of NHE-1
phosphorylation levels in DM-T2 and NDM samples; *P<0.04 vs remote NDM, **P<0.0001 vs remote DM-T2, #P<0.0001 vs NDM, n=20 per
group. D, Bar graph showing optical density analysis of phosphorylated NHE-1 to total NHE-1 ratio DM-T2 and NDM samples; *P<0.0001 vs
remote, #P<0.0001 vs NDM, n=20 per group. E and F, Representative confocal microscopy images showing NHE-1 localization and increased
expression within myocytes in DM-T2 vs NDM samples. Scale bar 20 lm. G and H, Bar graphs showing cardiomyocyte size and apoptosis in peri-
infarct areas of DM-T2 samples compared with NDM; *P<0.01 vs NDM, n=20 per group. (I through L) Representative confocal microscopy and
DAB-staining light microscopy images showing an activated caspase-3 (Act-Casp-3)–positive apoptotic myocyte in the peri-infarct zone of a DM-
T2 sample compared with NDM. Quantitative data are expressed as meanSE. DAB indicates 3,3′-diaminobenzidine; DM-T2, diabetes mellitus
type 2; NDM, non–diabetes mellitus; NHE-1, sodium-hydrogen exchanger-1; WB, Western blot.
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through 4D). The increased phosphorylation was confirmed
when normalizing for NHE-1 total protein levels (Figure 4A
through 4D). Immunofluorescence and confocal microscopy
detected NHE-1 expression specifically within myocytes that
was increased in DM-T2 versus NDM samples (Figure 4E
and 4F).
Because NHE-1 overexpression and hyperactivity mediate
maladaptive myocardial hypertrophy and death,14,16 we then
measured myocyte size and apoptosis in the samples from
patients included in the study. Myocyte hypertrophy and
apoptosis, evaluated by cell size and activated caspase-3
staining, respectively, were increased in peri-infarct areas of
DM-T2 samples compared with NDM samples (Figure 4G
through 4L).
Rat neonatal or adult cardiac myocytes (nCMs or arCMs,
respectively) were then isolated, transfected with a CA-II or
empty plasmid (Figure 5A), and exposed to NG or HG
concentration in the presence or absence of a specific
NHE-1 inhibitor, KR-32568, in vitro. CA-II induced CM
hypertrophic growth assessed by cell size measurement and
[3H]leucine incorporation at levels similar to HG treatment
(Figure 5B and 5C). CA-II inhibition by ETZ administration
reduced nCM hypertrophy induced by HG, while NHE-1
inhibition (KR-32568, named as NHE-1-i) prevented nCM
hypertrophy induced by CA-II overexpression (Figure 5B and
5C). ETZ and NHE-1-i, respectively reduced HG- and CA-II–
induced molecular hypertrophic response (Figure 5B and 5C).
ANF, BNP, and b-MHC mRNAs, markers of cardiac hypertro-
phy, were upregulated in nCMs treated with HG or CA-II
overexpression (Figure 5D). Furthermore, HG and CA-II over-
expression increased adult rat ventricular myocyte (arCM)
apoptosis as measured by TdT staining (Figure 5E). The latter
was attenuated by ETZ or NHE-1 inhibition, respectively
(Figure 5E). Finally, a specific shRNA silencing CA-II expres-
sion (CA-IIshRNA) was transfected in CMs and it blocked NHE-1
phosphorylation by HG (Figure 5F).
Thus, taken together, these data suggest that HG increases
myocyte CA-II expression, which hyperactivates NHE-1,
leading to increased maladaptive myocyte growth and apop-
totic death in ischemic diabetic cardiomyopathy.
miRNA-23b Is Downregulated in Cardiomyocytes
of Diabetic Ischemic Cardiomyopathy
The upregulation of CA-II expression within cardiac myocytes
in diabetic samples raised the question on how this is
regulated. MicroRNAs (miRNAs) are master regulators of gene
expression in plant and mammalian cells,29 and it was logical
to scan miRNA libraries for the different miRNAs potentially
involved in CA-II expression regulation. From the analysis of
the CA-II 3′-UTR by using the TargetScan algorithm, we
identified miRNA-23b, which has recently been linked to the
development of immune diseases and other disorders.30,31
miR-23b has been proposed to be a key regulator of cell cycle,
migration, apoptosis, and differentiation.30–33 Yet, little is
known about miR-23b expression and function in the adult
diabetic heart.
We first evaluated miR-23b expression in rat hearts
compared with other adult tissues. miR-23b was detectable
in the heart at levels comparable with the lungs and
expressed more compared with the liver, kidney, spleen,
and brain (Figure 6A). In particular, miR-23b was enriched in
rodent cardiomyocytes compared with cardiac endothelial
cells, smooth muscle cells, and fibroblasts (Figure 6B).
However, miR-23b myocyte levels were lower than known
cardiac-enriched miRNAs, like miR-1 (Figure 6C). We then
measured miR-23b expression in the cardiac samples from
DM-T2, compared with NDM patients. Intriguingly, miR-23b
was downregulated in the remote zone and even more in
the peri-infarct zone of DM-T2 compared with NDM
(Figure 6D). Accordingly, 48 hours of HG treatment of both
nCMs and arCMs significantly reduced miR-23b levels while
increasing CA-II mRNA and protein levels in vitro (Figure 6E
and 6F).
Thus, these data show that miR-23b is normally expressed
in healthy mammalian myocardium and that it is significantly
downregulated in the stressed myocardium of diabetic
ischemic cardiomyopathy. As miR-23b putatively targets CA-
II, it may be a main player in the detrimental effect of CA-II
overexpression in diabetic cardiomyopathy.
miR-23b Directly Targets CA-II Expression and
Modulates HG-Induced Myocyte Hypertrophy and
Death In Vitro
We first assessed the effects of miR-23b gain and loss of
function on myocyte hypertrophy in nCMs and death in arCMs
in vitro. nCMs or arCMs were transfected with an miR-23b
precursor or an miR-23b inhibitor (anti–miR-23b) in vitro. miR-
23b precursor overexpression significantly increased the
expression of miR-23b in both nCMs and arCMs (Figure 7A).
miR-23b overexpression reduced HG-induced nCM hypertro-
phic growth, while miR-23b inhibition per se induced nCM
growth in vitro (Figure 7B and 7C). The latter was counter-
acted by ETZ treatment (Figure 7B and 7C). Accordingly, miR-
23b overexpression reduced HG-induced arCM apoptosis,
while EZT treatment prevented anti–miR-23b–induced arCM
apoptotic death in vitro (Figure 7D). mRNA levels of CA-II
were reduced or increased when overexpressing or inhibiting
miR-23b, respectively (Figure 7E). Importantly, miR-23b over-
expression reduced HG-induced CA-II expression in nCMs
(Figure 7E). Moreover, a luciferase reporter fused to the 3′
untranslated region (UTR) of CA-II was repressed by miR-23b
transfection in mouse C2C12 myoblast cells, and this
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repression was abolished when the miR-23b seed-comple-
mentary sequence was mutated (Figure 7F). Finally, a CA-II
construct lacking the UTRs (CA-II-1–D3′-UTR), and therefore
not targeted by miR-23b, completely reverted the reduced
myocyte hypertrophy that we observed after miR-23b over-
expression in HG-treated nCMs in vitro (Figure 7G).
Thus, these data show that miR-23b directly regulates CA-II
expression and suggest that miR-23 downregulation releases
Figure 5. Carbonic anhydrase (CA)-II exacerbates cardiomyocyte hypertrophy and death in vitro. A, CA-II
overexpression in neonatal and adult cardiomyocytes (nCMs and arCMs, respectively); *P<0.001 vs control
empty plasmid (CON). B, Effects of normal/low glucose (CON), high glucose (HG), CA-II overexpression, CA-
II inhibition by ETZ, and specific NHE-1 inhibitor (NHE-1-i) on nCM cell size; *P<0.004 vs CON, ETZ, HG+ETZ,
NHE-1-i and CA-II+NHE-1-i. When not specified, drug treated cells were grown in normal/low glucose. C,
Effects of normal/low glucose (CON), high glucose, CA-II overexpression, CA-II inhibition by ETZ, and
specific NHE-1 inhibitor (NHE-1-i) on nCM hypertrophic growth assessed by [3H]leucine incorporation;
*P<0.001 vs CON, ETZ, HG+ETZ, NHE-1-I, and CA-II+NHE-1i. D, Effects of normal/low glucose (CON), high
glucose, CA-II overexpression, CA-II inhibition by ETZ, and specific NHE-1 inhibitor (NHE-1-i) on ANF, BNP
and b-MHC mRNA levels in nCMs; *P<0.001 vs CON, ETZ, HG+ETZ, NHE-1-i and CA-II+NHE-1i. E, Effects of
normal/low glucose (CON), high glucose, CA-II overexpression, CA-II inhibition by ETZ, and specific NHE-1
inhibitor (NHE-1-i) on arCM apoptosis; *P<0.001 vs CON, ETZ, HG+ETZ, NHE-1-i and CA-II+NHE-1i. F,
Effects of scrambled control shRNA (CTRLshRNA) and specific CA-II shRNA (CA-IIshRNA) on glucose-induced
NHE-1 phosphorylation. All quantitative data are from 4 independent experiments. Quantitative data are
expressed as meanSE. EZT indicates 6-ethoxyzolamide; NHE-1, sodium-hydrogen exchanger-1.
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CA-II within myocytes, leading to increased myocyte hyper-
trophy and death in DM-T2.
miR-23b Downregulation Is Dependent on p38
Mitogen-Activated Protein Kinase Pathway
The mitogen-activated protein kinase (MAPK) activation is
regulated by miR-23b.34 Accordingly, maladaptive myocyte
hypertrophy and increased myocyte death in diabetic cardio-
myopathy are regulated by p38 MAPK activity.34–36 Thus, to
assess the relationship between miR-23b and MAPK signaling
pathway in cardiac myocytes and DM-T2, the activation of
p38 MAPK, ERK1/2, and JNK was evaluated by Western
blotting both in the myocardial samples from DM-T2 and NDM
patients and in HG-treated CMs in vitro. As shown in
Figure 8A, the 3 MAPKs were significantly phosphorylated in
the myocardial samples from DM-T2 compared with NDM.
Also, HG treatment significantly increased the phosphoryla-
tion levels of p38, ERK1/2, and JNK in nCMs and arVMs in
vitro (Figure 8B and 8C). To further explore the functional
relationship between miR-23b and p38, ERK1/2, and JNK
activity, we used specific inhibitors of the 3 MAPKs, SB-
203580, SP-600125, and PD-98059, respectively, to test
whether inhibition of p38, ERK1/2, and JNK could influence
the effect of miR-23b on cardiomyocyte growth and survival.
Of note, the p38 MAPK inhibitor SB203580 significantly
increased miR-23b while reducing CA-II levels in HG-treated
nCMs and arCMs, whereas SP600125 or PD98059 (JNK and
ERK1/2 inhibitors, respectively) had no such effect (Fig-
ure 8D and 8E). Concurrently, SB203580 reduced HG-
induced nCM hypertrophy and arCM apoptotic death (Fig-
ure 8F and 8G).
Overall, these data point to a molecular mechanism
whereby HG concentration in DM triggers MAPK cascade in
Figure 6. MicroRNA-23b (miR-23b) is downregulated in cardiomyocytes of diabetic ischemic cardiomyopathy. A, miR-23b expression in rat
hearts as compared with other adult tissues, *P<0.0001 vs other tissues. B, miR-23b levels in nCMs and arCMs compared with aortic endothelial
cells (AoECs) and smooth muscle cells (AoSMCs). *P<0.0001 vs AoECs, AoSMCs, and nCMs. C, miR-23b and miR-1 levels in nCMs and arCMs;
*P<0.0001 vs miR-1, #P<0.01 vs nCMs. D, miR-23b levels in the remote zone in the peri-infarct zone of DM-T2 compared with NDM; *P<0.0001
vs NDM, #P<0.0001 vs remote zone. E, The 48-hour high glucose (HG) treatment of both NCMs and arCMs significantly reduced miR-23b levels
compared with low/normal glucose controls (CON); *P<0.001 vs CON. F, The 48-hour HG treatment of both nCMs and arCMs significantly
increased CA-II mRNA levels in vitro compared with low/normal glucose controls (CON); *P<0.001 vs CON. All quantitative data are from 4
independent experiments. Quantitative data are expressed as meanSE. arCM indicates adult ventricular cardiomyocyte; DM-T2, diabetes
mellitus type 2; nCM, neonatal cardiomyocyte; NDM, non–diabetes mellitus.
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Figure 7. MicroR-23b (miR-23b) directly targets CA-II expression and modulate myocyte hypertrophy and death in vitro. A, miR-23b precursor
transfection increased miR-23b levels in nCMs and arCMs in vitro compared with miR-scrambled precursor (CON); *P<0.001 vs CON. B, Effects of
normal/low glucose (CON), high glucose (HG), ETZ, miR-23b precursor, and anti–miR-23b on nCM hypertrophic growth assessed by [3H]leucine
incorporation; *P<0.03 vs CON, ETZ, miR-23b, HG+miR-23b, and anti–miR23b+ETZ. When not specified, drug treated or transfected cells were
grown in normal/low glucose. C, Effects of normal/low glucose (CON), high glucose (HG), ETZ, miR-23b precursor, and anti–miR-23b on ANF,
BNP, and b-MHC mRNA levels in nCMs in vitro; *P<0.03 vs CON, ETZ, miR-23b, HG+miR-23b, and anti–miR23b+ETZ. D, Effects of normal/low
glucose (CON), high glucose (HG), ETZ, miR-23b precursor, and anti–miR-23b on arCM apoptotic death in vitro; *P<0.01 vs CON, ETZ, miR-23b,
HG+miR-23b, and anti–miR23b+ETZ. E, mRNA levels of CA-II in nCMs cultured in low/normal glucose (CON) or high glucose (HG) and transfected
with miR-23b precursor or anti–miR-23b; *P<0.001 vs CON; #P<0.03 vs all. F, Luciferase activity of wild-type (WT) and mutant (Mut) CA-II 3′-UTR
sequences separately co-transfected with miR-23b precursor or anti–miR-23b into C2C12 myoblasts. *P<0.01 vs all. G, Effects of normal/low
glucose (CON), high glucose (HG), miR-23b precursor, and a mutant CA-II construct (lacking the 3′-UTRs, CA-IImut) on nCM cell size in vitro;
*P<0.003 vs all, #P<0.03 vs HG. All quantitative data are from 4 independent experiments. Quantitative data are expressed as meanSE. arCM
indicates adult ventricular cardiomyocyte; EZT, 6-ethoxyzolamide; nCM, neonatal cardiomyocyte; UTR, untranslated region.
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CMs leading to p38 activation, which downregulates miR-23b
that removes its repression on CA-II. Increased levels of CA-II
hyperphosphorylate NHE-1, leading to the worsened mal-
adaptive cardiomyocyte growth and ensuing death in diabetic
cardiomyopathy.
Discussion
The main findings emanating from this study are that (1) CA-I
and CA-II are overexpressed in diabetic ischemic human
myocardium; (2) CA-I is involved in the reduced capillary density
in the ischemic diabeticmyocardium; (3) increasedmyocyte CA-
II is associated with NHE-1 hyperphosphorylation in diabetic
ischemic cardiomyopathy; (4) miRNA-23b directly targets CA-II
for repression, and it is downregulated in cardiomyocytes of
diabetic ischemic cardiomyopathy; and (5) miR-23b regulation
by hyperglycemia depends on p38MAPK activity andmodulates
HG-induced myocyte hypertrophy and death in vitro.
Burgeoning evidences point to a detrimental prohypertro-
phic role of CA-II in rodent and human hearts.12, 13 In the
clinical setting, it is worth remembering that the membrane-
permeant CA inhibitor acetazolamide (ACTZ) has been histor-
ically used as a diuretic (before the introduction of loop
diuretics) in patients with severe congestive heart failure,37
and the status of congestive heart failure in all patients
receiving ACTZ at that time substantially improved.38
Recently, ACTZ has been safely used in pediatric patients
with heart disease.39 Moreover, the GUARDIAN Trial 40 and
the ESCAMI Trial,41 assessing the effects of NHE-1 inhibition
in ischemic cardiomyopathy, have shown promising results.
Here we show that HG-induced myocyte hypertrophy and
death correlate with CA-II expression and are prevented by
NHE-1 inhibition. In some studies, increased cardiac expres-
sion of NHE-1 protein appears to be involved in the
subsequent pathological changes.42 In human heart failure,
however, enhanced NHE-1 activity has not been correlated
with increased NHE-1 expression, suggesting a role for
activation by posttranslational mechanisms.43 It is interesting
to note that in the present study, we show that diabetic
cardiomyopathy is characterized by an increased NHE1
protein expression along with its exaggerated posttranslation
phosphorylation. Thus, the 2 mechanisms appear to have an
additive detrimental effect on the maladaptive cardiomyocyte
growth and ensuing death in the diabetic myocardium.
A decrease in capillary density due to an increase in
endothelial cell apoptosis in the heart is implicated in cardiac
ischemia in DM.28 These perturbations in vascular cell homeo-
stasis are linked to the development of pathologies affecting
large-vessel (atherosclerosis and cardiomyopathy) and small-
vessel (retinopathy, nephropathy, and neuropathy) diabetic
complications. Recently, it has been shown that increased
extracellular carbonic CA-I leads to an excessive hemorrhagic
retinal vascular permeability contributing to the pathogenesis
of proliferative diabetic retinopathy.17 Intriguingly, we show
here that CA-I is overly expressed in the human diabetic
ischemicmyocardium, andCA-I appears tomediate HG-induced
altered endothelial permeability as well as the decreased
capillary density in diabetic ischemic cardiomyopathy. Further-
more, the increase in CA-I expression in the interstitium
suggests that other cardiac cell types could be involved in CA-I
overexpression. While no strong evidence is available on a
direct role of CA-I on cardiac fibroblasts, CA-I (as well as other
CAs) is expressed by human monocytes,8 which have an
established role in cardiac inflammation and fibrosis in the
ischemic myocardium. Thus, it is highly tempting to speculate a
potential role for CA-I in cardiac fibrosis to be tested in future
studies. Overall, these observations postulate that CA-I inhibi-
tion, currently clinically investigated for the treatment of
diabetic retinopathy, may be a potential novel therapeutic
approach for diabetic cardiovascular disease.
Increasing evidence indicates that miRNAs regulate key
genetic programs in cardiovascular biology, physiology, and
disease.44 In particular, several miRNAs are responsible for
the pathogenesis of post-ischemic heart failure, and recently a
set of miRNAs have been found to be deregulated in
experimental diabetes 34 and in diabetic versus nondiabetic
patients with post-MI heart failure.45 Thus, miRNA network
dysregulation is viewed as a gatekeeper underlying the
specific ischemic cardiomyopathy mechanisms differentiating
diabetic patients.46,47 In the present report, we show for the
first time that miR-23b is specifically downregulated in the
cardiac samples from diabetic patients with ischemic cardio-
myopathy. miR-23b levels inversely correlate with CA-II, and
we demonstrated that CA-II is a bona fide target of miR-23b
gene-silencing activity, which is removed via HG concentra-
tion through a molecular mechanism involving p38 activation.
It is also interesting that miR-23b has a potent immune
modulatory role in different diseases.30,31 Thus, it is possible
that miR-23b downregulation in the ischemic diabetic myo-
cardium could contribute to the detrimental immune activa-
tion in DM.4 Moreover, our data raise the hypothesis that
miR23b modulation in vivo could affect CA-II regulation and
post-MI remodeling. The latter should be directly tested in
future studies by myocyte-specific miR-23b gain and loss of
function in genetically modified animals.
Finally, it is highly tempting to speculate the potential
clinical relevance of the findings from the present study.
Indeed, CA inhibition with existing drugs could be readily and
specifically adopted for diabetic patients with post-MI heart
failure as adjuvant diuretic therapy, on one hand, and as
specific treatment for the exaggerated pathological remodel-
ing of the ischemic diabetic heart, on the other. Nevertheless,
further studies are warranted to test experimentally such
hypothesis before it is tested in the clinical human scenario.
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Figure 8. MicroR-23b (miR-23b) downregulation is dependent on p38 MAPK pathway. A, p38 MAPK, ERK1/2, and JNK were significantly more
phosphorylated in the myocardial samples from T2-DM compared with NDM as shown by representative Western blots and O.D. semiquantitative
analysis; *P<0.001 vs NDM, n=20 per group. B, High glucose (HG) significantly increased the phosphorylation levels of p38, ERK1/2, and JNK in
nCMs in vitro. *P<0.001 vs normal glucose (NG), n=4 per group. C, HG significantly increased the phosphorylation levels of p38, ERK1/2, and JNK
in arCMs in vitro. *P<0.0001 vs NG, n=4 per group. D, SB-203580, PD-98059, and SP-600125 (p38, ERK1/2, and JNK specific inhibitors,
respectively) effects on miR-23b levels in high-glucose (HG) treated nCMs or arCMs in vitro. *P<0.001 vs normal glucose (NG). E, SB-203580, PD-
98059, and SP-600125 effects on CA-II mRNA levels in high-glucose (HG)-treated nCMs or arCMs in vitro. *P<0.03 vs normal glucose (NG), n=4
per group. F, SB-203580 reduced HG-induced nCM growth in vitro. *P<0.003 vs normal glucose (CON), n=4 per group. G, SB-203580 reduced
HG-induced arCM apoptosis in vitro. *P<0.0008 vs normal glucose (CON), n=4 per group. Quantitative data are expressed as meanSE. DM-T2
indicates diabetes mellitus type 2; nCM, neonatal cardiomyocyte; arCM, adult ventricular cardiomyocyte; NDM, non–diabetes mellitus.
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In the present study, we have obtained strong evidence that
CA-I and CA-II are significantly induced in the diabetic human
myocardium compared with nondiabetic heart tissues. How-
ever, as it was impossible for ethical and logical reasons to
obtain left ventricular tissues from matched healthy donors,
no direct data could be provided to actually show that
ischemic heart disease itself affects CA expression by
comparing ischemic tissues in diabetic or nondiabetic
patients with nonischemic tissues. Despite that, the increased
CA expression in the peri-infarct versus the remote zone
provides a good indication that ischemia is indeed an inducer
of myocardial CA-I and CA-II expression. Also, we would like to
point out that the recent report by Alvarez et al has already
shown that failing human hearts (of ischemic and nonischem-
ic origin) of nondiabetic patients are characterized by an
increased CA-II expression.13
We have not performed an animal study using a diabetic
animal model to directly provide a causal relationship for our
findings on human samples. However, previous studies have
established that CA plays a major role in pathological cardiac
remodeling in different animal models.9–12 Yet, the extensive
in vitro gain- and loss-of-function data on endothelial cells and
neonatal and adult myocytes supports a causal relationship
for the observations made on human samples, which should
be verified in future studies by the indisputable and additional
value of in vivo animal experiments.
In the present study, we have endeavored to specifically
explain how DM regulates CA-II increase in cardiomyocytes
while we have not experimentally tested the mechanisms
underlying CA-I–increased expression by DM. Our findings
show that hyperglycemia through a p38/miR-23b–depen-
dent mechanism increases CA-II in myocytes. In Figure 2, we
show that CA-I inhibition prevents hyperglycemia-induced
endothelial cell death and altered permeability. The latter
finding suggests that hyperglycemia is a strong inducer of
CA-I in endothelial cells. It is known that hyperglycemia
induces MAPK-p38 activation in endothelial cells and that
p38 inhibition prevents endothelial cell damage by hyper-
glycemia.48 Thus, this evidence also suggests that a
mechanism similar to that underlying CA-II increase in
myocytes by DM may also explain CA-I increase in
endothelial cells by DM. Of course, this hypothesis remains
highly speculative, and it remains to be properly tested in
future studies.
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